wsbdaily | Tue, 20 Dec 2022 03:11:26 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
InMed Pharmaceuticals Inc.(INM)
InMed Pharmaceuticals Inc.
815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and nov... Read More
Summary & Charts
| Price | $ 2.62 | -0.23 (-8.08%) |
| Day's Range | $ 2.61 - 2.85 | |
| Previous Close | $ 2.85 | |
| Market Cap | $ 2.85M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqCM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 94.88K | |
| Avg. Volume (20 day) | 1.79M | |
| Rel. Volume (20 day) | 0.05 | |
| Rel. Volume (3 month) | 0.05 | |
| Rating | B | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 32.49 % | Neutral |
| ROE | -169.59 % | Strong Sell |
| ROA | -152.91 % | Sell |
| P/E | -2.25 % | Neutral |
| P/B | 0.21 % | Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | $ 2.64 | $ 2.85 | $ 2.61 | $ 2.62 | -0.23 | 94,884 | 0.05 | 0.05 | 1 |
| Nov 25, 2022 | $ 2.60 | $ 2.90 | $ 2.60 | $ 2.85 | +0.17 | 189,367 | 0.11 | 0.11 | |
| Nov 23, 2022 | $ 2.63 | $ 2.73 | $ 2.52 | $ 2.68 | -0.04 | 260,013 | 0.15 | 0.15 | |
| Nov 22, 2022 | $ 2.55 | $ 3.02 | $ 2.52 | $ 2.72 | +0.13 | 487,112 | 0.27 | 0.29 | |
| Nov 21, 2022 | $ 2.70 | $ 2.70 | $ 2.52 | $ 2.59 | -0.17 | 138,863 | 0.08 | 0.08 | |
| Nov 18, 2022 | $ 3.29 | $ 3.39 | $ 2.72 | $ 2.76 | -1.08 | 888,230 | 0.49 | 0.54 | |
| Nov 17, 2022 | $ 3.40 | $ 4.62 | $ 3.37 | $ 3.84 | +0.05 | 4,064,266 | 2.30 | 2.52 | |
| Nov 16, 2022 | $ 3.14 | $ 4.75 | $ 3.06 | $ 3.79 | +1.01 | 28,392,611 | 18.14 | 18.47 | 1 |
| Nov 15, 2022 | $ 3.23 | $ 3.68 | $ 2.54 | $ 2.78 | 660,273 | 4.44 | 0.58 | 1 | |
| Nov 14, 2022 | $ 2.87 | $ 3.09 | $ 2.77 | $ 2.78 | -0.22 | 66,244 | 0.56 | 0.06 | |
| Nov 11, 2022 | $ 2.85 | $ 3.24 | $ 2.72 | $ 3.00 | +0.13 | 150,226 | 1.29 | 0.14 | |
| Nov 10, 2022 | $ 2.75 | $ 2.94 | $ 2.65 | $ 2.87 | +0.22 | 65,125 | 0.55 | 0.06 | |
| Nov 09, 2022 | $ 2.43 | $ 2.88 | $ 2.43 | $ 2.65 | +0.14 | 59,355 | 0.51 | 0.05 | |
| Nov 08, 2022 | $ 2.54 | $ 2.63 | $ 2.41 | $ 2.51 | -0.06 | 46,432 | 0.40 | 0.04 | |
| Nov 07, 2022 | $ 2.47 | $ 2.63 | $ 2.47 | $ 2.57 | +0.07 | 18,941 | 0.15 | 0.02 | |
| Nov 04, 2022 | $ 2.82 | $ 2.84 | $ 2.43 | $ 2.50 | -0.32 | 71,069 | 0.49 | 0.06 | |
| Nov 03, 2022 | $ 2.95 | $ 3.03 | $ 2.80 | $ 2.82 | -0.15 | 42,788 | 0.29 | 0.04 | |
| Nov 02, 2022 | $ 3.13 | $ 3.30 | $ 2.96 | $ 2.97 | -0.20 | 43,537 | 0.28 | 0.04 | |
| Nov 01, 2022 | $ 3.06 | $ 3.28 | $ 3.06 | $ 3.17 | +0.12 | 30,663 | 0.19 | 0.03 | |
| Oct 31, 2022 | $ 3.22 | $ 3.23 | $ 3.02 | $ 3.05 | -0.24 | 77,997 | 0.48 | 0.06 |
News
The latest news about InMed Pharmaceuticals Inc. (INM).
Zacks Investment Research | 2022-11-17 12:02:21
InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
Market Watch | 2022-11-16 12:13:13
Shares of InMed Pharmaceuticals Inc. INM, +52.16% rocketed 50.9% on very heavy volume in midday trading Wednesday, after the company said it was awarded a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support research and development of its cannabinoid drug candidates for the potential treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's. Trading volume spiked to 19.5 million shares, compared with the full-day average of about 148,200 shares.
Seeking Alpha | 2022-09-23 15:28:08
InMed Pharmaceuticals Inc. (NASDAQ:INM ) Q4 2022 Results Conference Call September 23, 2022 1:00 PM ET Company Participants Colin Clancy - VP, IR Eric Adams - President and CEO Michael Woudenberg - COO Brenda Edwards - Interim CFO Dr. Eric Hsu - SVP, Preclinical Research and Development Conference Call Participants Scott Henry - ROTH Capital Partners Raghuram Selvaraju - H.C. Wainwright Operator Good day.
GlobeNewsWire | 2022-09-19 18:00:00
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-11 | BMO | -- | -- | -- | -- | -- | -- |
| 2022-09-23 | BMO | -5.5 | -14.03 | 155.09% | 0.5M | 1.1K | -99.79% |
| 2022-05-13 | BMO | -6.25 | -6.25 | -- | 310K | 310 | -99.9% |
| 2022-02-14 | BMO | -6 | -7.75 | 29.16% | 120K | -- | -- |
| 2021-11-10 | BMO | -8.75 | -6.25 | 28.58% | -- | -- | -- |
| 2021-09-24 | BMO | -8.5 | -10.25 | 20.58% | -- | -- | -- |
| 2021-05-13 | BMO | -6 | -10.25 | 70.83% | -- | -- | -- |
| 2021-02-11 | BMO | -6 | -9.25 | 54.16% | -- | -- | -- |
Top Discussions
These are the top discussions over the last 24-hours that mention the INM stock ticker symbol.
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily